Emily Sobel

Emily Sobel provides research and strategic support to health plans and pharmaceutical clients on federal and state health policy activities.

With experience spanning the pharmaceutical industry, provider associations, and advocacy groups, she assists clients in analyzing and reacting to diverse health policy issues.

Prior to joining Avalere, Emily was an associate consultant on the healthcare team at APCO Worldwide, providing strategic policy and issues management counsel to private sector clients across the healthcare industry, including policy and regulatory landscape analysis to inform advocacy and product decisions. Prior to that, as a federal government affairs analyst at Sanofi US, she conducted research on national and global healthcare policy issues with a focus on the Affordable Care Act and vaccines.

Emily has a BA from Duke University in public policy studies.

Authored Content

A new claims-based analysis from Avalere examined vaccine uptake among low-income adolescents enrolled in Medicaid Managed Care and found a 26% decline in routine vaccinations when comparing March–October 2019 to the same period in 2020.

Immunization Information Systems (IIS), or immunization registries, are used across the US to provide consolidated and complete accounts of patient immunization history in a given city, state, or region.

The proposed CY 2020 MPFS rule includes provisions that, if finalized, would increase provider reimbursement for vaccine administration. However, the proposed crosswalk of the codes to a separate, nonvaccine related code could subject the code to future unrelated payment fluctuations.

Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.

A proposal to eliminate shoulder injuries from the list of vaccine-related conditions that warrant federal compensation through the National Vaccine Injury Compensation Program (VICP) highlights the administrative challenges posed by these claims and provides an opportunity to consider reforms to modernize the program.

Although influenza disease burden is high, vaccine uptake remains low.

On December 16, Avalere policy experts, including Senior Adviser Dr. Angela Shen, published a piece in Health Affairs blog entitled “Shaping the 2020 National Vaccine Plan.” It explores the progress to date against the 2010 National Vaccine Plan (NVP), recurring challenges, and the 2020 NVP.

Two decisions finalized in the CY 2020 Medicare Physician Fee Schedule (MPFS) rule have important implications for vaccine policy and access.

Since the 1980s, all 50 states have used immunization requirements as a condition of school entry to protect the public’s health from vaccine-preventable diseases.

An April 9 hearing before the Senate Finance Committee entitled “Drug Pricing in America: A Prescription for Change” included discussion related to cost-sharing for preventive services in the Medicare Part D.

With the number of measles cases rising across the country, FDA Commissioner Scott Gottlieb raised the prospect of federal intervention over exemptions to state-level immunization school-entry requirements. While not specifying what role the federal government would play, Gottlieb stated, “You could mandate certain rules about what is and isn’t permissible when it comes to allowing people to have exemptions.”

Nearly 80,000 people died during the 2017–2018 influenza season. Only 37% of adults were vaccinated. Several novel emerging products could make vaccination more accessible and effective, potentially reshaping the market and lowering influenza disease burden.

On June 14, Avalere experts came together with Cynthia Tudor, former Deputy Center Director of the Center for Medicare and Senior Advisor to Avalere, to discuss vaccine coverage and access challenges under Medicare.

A proposed shift of Part B drugs into Part D could affect patient access and increase the burden on providers.

Avalere experts discuss adult immunization rates in the United States and how the disparate coverage of vaccines under Medicare creates significant barriers to increasing adult immunization uptake.

States can pursue various policy opportunities to encourage vaccination and increase access to vaccines.

Avalere has released a new white paper explaining the current insurance coverage requirements for vaccines and the laws that govern those requirements for the Medicare (Parts B and D), Medicaid, and commercial (group and individual) markets.